CymaBay Therapeutics, Inc. (CBAY)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.5900 |
| Open | 2.6100 |
| Bid | 2.5900 x 1300 |
| Ask | 2.7600 x 3200 |
| Day's Range | 2.3300 - 2.8200 |
| 52 Week Range | 1.6700 - 4.7900 |
| Volume | |
| Avg. Volume | 754,438 |
| Market Cap | 238.767M |
| Beta (5Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1480 |
| Earnings Date | Mar 23, 2022 - Mar 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.89 |
- GlobeNewswire
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022
Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival NEWARK, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced encouraging seladelpar data in patients with primary biliary cholangitis (PBC) that are being presented at The International Liver Congress™ 2022 of the European A
- Simply Wall St.
Trade Alert: The President Of CymaBay Therapeutics, Inc. (NASDAQ:CBAY), Sujal Shah, Has Just Spent US$100k Buying 43% More Shares
Potential CymaBay Therapeutics, Inc. ( NASDAQ:CBAY ) shareholders may wish to note that the President, Sujal Shah...
- GlobeNewswire
CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2022
NEWARK, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be delivered during The International Liver Congress™ 2022 of the European Association for the Study of Liver (EASL) which will be held in London, UK from June 22nd – 26th. A poster presentation1 in collaboration
